Cargando…
Structural basis for differential p19 targeting by IL-23 biologics
BACKGROUND: IL-23 is central to the pathogenesis of psoriasis, and is structurally comprised of p19 and p40 subunits. “Targeted” IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab differ mechanistically from ustekinumab because they bind p19, whereas ustekinumab binds p40; however, a knowl...
Autores principales: | Daniele, Stefano G., Eldirany, Sherif A., Ho, Minh, Bunick, Christopher G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029002/ https://www.ncbi.nlm.nih.gov/pubmed/36945513 http://dx.doi.org/10.1101/2023.03.09.531913 |
Ejemplares similares
-
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy
por: Eldirany, Sherif A., et al.
Publicado: (2020) -
Molecular Modeling of Pathogenic Mutations in the Keratin 1B Domain
por: Hinbest, Alexander J., et al.
Publicado: (2020) -
Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts
por: Lomakin, Ivan B., et al.
Publicado: (2020) -
Ixekizumab-induced alopecia areata
por: Eldirany, Sherif A., et al.
Publicado: (2019) -
Dermatomyositis associated with an adrenal adenoma
por: Eldirany, Sherif A., et al.
Publicado: (2021)